论文部分内容阅读
目的探讨动脉化疗栓塞联合增强放射治疗治疗难治性骨盆软骨瘤的效果。方法选取2011年1月至2013年12月间收治的难治性骨盆软骨瘤患者70例,根据治疗方法不同分为接受动脉化疗栓塞联合增强放射治疗的观察组和接受全身化疗联合增强放射治疗的对照组,每组35例,比较两组患者的存活情况、不良反应以及血管新生指标。结果观察组患者的1、2、3年生存率(91.4%、80.0%和60.0%)均明显高于对照组,其发生肾功能损伤、肝功能损伤、口腔黏膜炎、骨髓抑制和胃肠道反应的例数少于对照组,血管内皮生长因子(VEGF)A、VEGFB和VEGFC水平[(82.34±11.26)ng/ml、(77.92±9.54)ng/ml、(52.35±7.33)ng/ml]明显低于对照组。结论动脉化疗栓塞联合增强放射治疗有助于提高难治性骨盆软骨瘤患者的远期生存率,减少不良反应的发生率,并控制肿瘤血管新生,是治疗难治性骨盆软骨瘤的理想方法。
Objective To investigate the effect of arterial chemoembolization combined with enhanced radiotherapy in the treatment of refractory pelvic chondroma. Methods Seventy patients with refractory pelvic chondroma treated between January 2011 and December 2013 were divided into two groups: observation group receiving arterial chemoembolization plus enhanced radiotherapy and group receiving systemic chemotherapy combined with enhanced radiotherapy Control group, 35 cases in each group. The survival, adverse reactions and angiogenesis indexes of two groups were compared. Results The 1-, 2- and 3-year survival rates (91.4%, 80.0% and 60.0%) in the observation group were significantly higher than those in the control group, with renal dysfunction, liver damage, oral mucositis, myelosuppression and gastrointestinal The number of response cases was less than that of the control group, and the levels of VEGF A, VEGFB and VEGFC [(82.34 ± 11.26) ng / ml, (77.92 ± 9.54) ng / ml and (52.35 ± 7.33) ng / Obviously lower than the control group. Conclusion Arteriochemoembolization combined with enhanced radiotherapy can improve long-term survival, reduce the incidence of adverse reactions, and control tumor angiogenesis in patients with refractory pelvic chondroma. It is an ideal method for the treatment of refractory pelvic chondroma.